News
The move combines Epsilogen’s clinical focus on immunoglobulin E (IgE) antibodies with TigaTx’s work on immunoglobulin A (IgA ...
U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback